| Literature DB >> 34944750 |
Katja Andrina Kravanja1, Matjaž Finšgar1.
Abstract
The development of bioactive coatings for orthopedic implants has been of great interest in recent years in order to achieve both early- and long-term osseointegration. Numerous bioactive materials have been investigated for this purpose, along with loading coatings with therapeutic agents (active compounds) that are released into the surrounding media in a controlled manner after surgery. This review initially focuses on the importance and usefulness of characterization techniques for bioactive coatings, allowing the detailed evaluation of coating properties and further improvements. Various advanced analytical techniques that have been used to characterize the structure, interactions, and morphology of the designed bioactive coatings are comprehensively described by means of time-of-flight secondary ion mass spectrometry (ToF-SIMS), X-ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FTIR), atomic force microscopy (AFM), scanning electron microscopy (SEM), transmission electron microscopy (TEM), 3D tomography, quartz crystal microbalance (QCM), coating adhesion, and contact angle (CA) measurements. Secondly, the design of controlled-release systems, the determination of drug release kinetics, and recent advances in drug release from bioactive coatings are addressed as the evaluation thereof is crucial for improving the synthesis parameters in designing optimal bioactive coatings.Entities:
Keywords: bioactive coatings; characterization techniques; controlled drug release; orthopedic implants
Year: 2021 PMID: 34944750 PMCID: PMC8698289 DOI: 10.3390/biomedicines9121936
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1ToF-SIMS mapping of the coating on AISI 316LVM (a,c) and TiAlV (b,d) performed by summarizing positive ions at m/z 339.99 and 341.99 (a,b) and negative ion sat m/z 26.00 for CN− (c,d) [57]. Reprinted from Progress in Organic Coatings, 158, Finšgar et al., The development and characterization of bioactive coatings for local drug delivery in orthopedic applications, Copyright (2021), with permission from Elsevier.
Figure 2IR radiation path in the ATR-FTIR system [81]. Reprinted from Biochimica et Biophysica Acta (BBA)—Biomembranes, 1828, Yechiel Shai, ATR-FTIR studies in pore forming and membrane induced fusion peptides, 2306–2313, Copyright (2013), with permission from Elsevier.
A list of the chemical structures of bioactive coatings as a function of wavenumbers (cm−1) obtained using FTIR/ATR-FTIR.
| Drug/Bioactive Coating Material | Functional Groups | Wavenumber (cm−1) | References |
|---|---|---|---|
|
| |||
| Clindamycin | N–C=O stretching | 1682 and 1550 | [ |
| C–O stretching | 1038 and 1079 | ||
| S–C–H bending | 1209 and 1249 | ||
| DCF | R–C=O stretching | 1305, 1500–1750 | [ |
| R=C=O stretching | 1577 | ||
| C–Cl stretching | 650–780 | ||
| HC–N–CH bending | 1376 | ||
| CH2 bending | 1462 | ||
| Vancomycin | C–H | 3284 | [ |
| Rifampicin | C–H | 2880 | [ |
| OH− | 3480 | ||
| furanone (C=O) | 1644 | ||
| acetyl (C=O) | 1725 | ||
| (C=O) | 1567 | ||
| N–CH3 | 2878 | ||
| Enrofloxacin | C=O | 1731 | [ |
| OH bending | 1631 | ||
| COO–stretching | 1508 | ||
| COO− | 1477 | ||
| Dexamethason | P–O | 1041 | [ |
| Ibuprofen | C=O stretching | 1720 | [ |
| C=C of the phenyl ring | 1513 | ||
| C–H | 1463 and 1378 | ||
|
| |||
| PCL | asymmetric C=H stretching | 2939 | [ |
| symmetric C=H stretching | 2864 | ||
| C=O stretching | 1730 | ||
| C–O/C–C stretching | 1294 | ||
| asymmetric C–O–C stretching | 1240 | ||
| asymmetric CH2 stretching | 2944 and 2865 | ||
| Poly(lactic-co glycolic acid) (PLGA) | C–H | 3000–2850 | [ |
| CHI | O–H | 3700–3000 | [ |
| Amide NHCOCH3 | 1643 and 1540 | ||
| NH2 stretching | 3430 | ||
| NH stretching | 1654 | ||
| CH scissoring | 1422–1380 | ||
| CH stretching | 2920 | ||
| C–O–C stretching | 900; | ||
| Poly(methyl methacrylate) (PMMA) | C–O–C symmetric stretching | 1149 | [ |
| CH2 bending | 1439 | ||
| C=O stretching | 1721 | ||
| asymmetric CH3 stretching | 2951 | ||
| Polyvinyl alcohol (PVA) | OH stretching | 3520 | [ |
| OH bending | 1440 | ||
| asymmetric CH2 stretching | 2910 | ||
| C–O stretching | 1067 | ||
| C=O stretching | 1740 | ||
| Alginate | symmetric COO−stretching | 1620 and 1413 | [ |
| COOH stretching | 1723 | ||
| Carboxymethyl cellulose (CMC) | Carboxylate group | 1630 | [ |
| O–H | 3200–3400 | ||
| C–OH stretching | 1000–1250 | [ | |
| C–O–C bending | |||
| Polydopamine | OH stretching | 3348 | [ |
| NH stretching | 3176 | ||
|
| |||
| HA | PO43− | 956, 1055, and 1101; | [ |
| CO23− | 854, 1410 | ||
| OH– | 3484 | ||
| BG | Si–O–Si bending | 450 | [ |
| Si–O–Si stretching | 930; | ||
| P–O stretching | 1015 | ||
| TNTs | Ti–O | 480; | [ |
| TiO–H | 3396 | ||
| Ti-O-Ti | 540 | ||
| TiO2 | Ti–O | 800 | [ |
| Single-walled carbon nanotubes | C–O | 1112 | [ |
| C–C | 1630 | ||
| C=O | 1730 | ||
| O–H | 3440 |
AFM measurements of bioactive coatings on metallic substrates.
| Coating Deposition Technique | Implant and Coating Materials | AFM Specifications | Information Obtained | References |
|---|---|---|---|---|
| Anodization | Ti substrate, TNT coatings | Tapping mode, tapping cantilever tips (NSC15/NoAl), a scanning size of 1.0 µm2 | Higher surface roughness compared to bare substrate, which contributes to an increase in the osteoblast adhesion and osseointegration of the implant material | [ |
| Layer-by-layer | Ti6Al4V alloy and AISI316LVM substrates, poly(2-hydroxyethyl methacrylate) (PHEMA), poly(2-hydroxypropylmethacrylate) (PHPMA), and sodium deoxycholate (NaDOC) coatings containing the anti-inflammatory drug DCF | Acoustic mode, in air at 25 °C, a scanning size of 1 × 1 µm2 | The coatings are structured in a particle-like form in the case of a polymer layer in the uppermost position, low values of roughness parameters with a decrease in scan size indicate flat morphologies on the substrate and very smooth coating layers | [ |
| AISI316LVM substrate, CHI and DCF coating layers | Tapping mode at room temperature, a sample size of 5 × 5 μm2, a resolution of 2048 × 2048 pixels, silicon cantilevers with a resonance frequency of 210–490 kHz, and a force constant of 12–110 N m−1 | Smaller and thinner surface interconnects in the case of a polymer layer in the uppermost position | [ | |
| AISI316LVM substrate, CMC and DCF coating layers | Acoustic mode with scan sizes of 10 × 10, 5 × 5, and 1 × 1 μm2, a resolution of at least 512 × 512 pixels, silicon cantilevers with a resonance frequency of 210–490 kHz and a force constant of 12–110 N m−1 | All samples showed similar results regarding topography, with substrate lines visible on all samples due to the grinding process, the roughness parameters slightly increased for the samples with the DCF layers on top | [ | |
| Ti substrate, coatings of poly(acrylic acid) (PAA) and poly(l-lysine) (PLL), with beta cyclodextrin (β-CD) complexes used to retain tetracycline (TC) | Peak-force tapping mode, silicon nitride cantilevers, a nominal spring constant of 0.7 N/m, and a scanning size of 2 × 2 mm | Significantly decreased values of roughness, suggesting that the incorporation of TC/anionic β-CD macromolecules smoothens the surface | [ | |
| 3D printing, electrospinning | 3D printing: Ti6Al4V and AISI 316LVM substrates, | Tapping mode, room temperature, silicon cantilevers, a resonance frequency of 210–490 kHz, a force constant of 12–110 N m−1, scanning sizes of 10 × 10 and 1 × 1 μm2, a resolution of 512 × 512 pixels | Relatively smooth surface of the noncoated coatings, functionalization with clindamycin showed no significant effect on the morphology and roughness of the samples, indicating a homogeneous distribution of the drug in the coating | [ |
| Grafting | Ti6Al4V substrate, coatings of polymers bearing sulfonate (styrene sodium sulfonate, NaSS) and carboxylate (methylacrylic acid, MA) groups | Contact mode, NP-S tips, a scan rate of 3.3 Hz, two images per sample were acquired from 41 × 41 µm2 areas and flattened by first-order line flattening | Increasing the oxidation treatment time from 1 to 3 min. resulted in a doubling of the surface roughness | [ |
| Drop casting | Ti substrate, CH/PVA coatings | Tapping mode, a scanning size of 1 × 1 μm2, the images are first-order x–y plane fitted and then first-order flattened using Nanoscope software (v1.30) | Nanometer-sized islands throughout the CH/PVA composite films, roughness, which promotes cell adhesion and proliferation, increased with the coating concentration | [ |
| Initiated chemical vapor deposition (iCVD) | Ti substrate, coatings of rhBMP-2 immobilized on glycidyl methacrylate (GMA) | A scanning area of 10 × 10 μm 2, room temperature | Smooth, bare, and pGMA-coated surface, a rough surface after functionalization with rhBMP-2 | [ |
Figure 3Micro-CT images of the transverse sections with a radius of 1 mm from implant surface of a canine femur 12 weeks after the implantation of bare Ti alloy, HA-, HT-, and Sr-HT-coated implants [138]. Reprinted from Biomaterials, 34, Zhang et al., The synergistic effect of hierarchical micro/nano-topography and bioactive ions for enhanced osseointegration, 3184-3195, Copyright (2013), with permission from Elsevier.
Figure 4A schematic representation of potential biological interactions with (A) hydrophilic and (B) hydrophobic surfaces. (A) hydrophilic surfaces interact with biological fluids, allow adsorption of proteins to the material surface, and facilitate interaction with cell receptors. (B) hydrophobic surfaces generally contain hydrocarbon contamination and consequently entrap air bubbles that inhibit protein adsorption and cell receptor activation [184]. Reprinted from Acta Biomaterialia, 10, Gittens et al., A review on the wettability of dental implant surfaces II: Biological and clinical aspects, 2907-2918, Copyright (2014), with permission from Elsevier.
Figure 5In vitro drug dissolution process with USP apparatus type I (rotating basket).
Kinetic models and their associated equations [205,207,208].
| Kinetic Models | Equations | |
|---|---|---|
| Zero-order |
| (4) |
| where | ||
| First-order |
| (5) |
| Higuchi |
| (6) |
| or a simplified Higuchi equation: | ||
|
| (7) | |
| where Q represents the amount of released drug at a given time and area, | ||
| Hixon–Crowell |
| (8) |
| where | ||
| Korsmeyer–Peppas |
| (9) |
| where | ||
| Baker–Lonsdale |
| (10) |
Figure 6A triphasic drug release profile with a short second phase (red), a burst drug release profile (yellow), a burst release profile with zero-order (orange), a zero-order drug release profile (blue), a triphasic release profile (green), and a biphasic drug release profile (black). Reprinted with permission from [209].
Coating-implant systems, the incorporated drugs, and the drug release characteristics.
| System | Drug | Drug Release | Reference |
|---|---|---|---|
|
| |||
| PCL/HA nanoparticle composite coatings on AZ31 Mg alloy | Simvastatin | Initial burst release controlled by diffusion (first day), followed by sustained release for up to 6 days controlled by polymer degradation | [ |
| PLGA on Ti | Aspirin | Prolonged release: | [ |
| Vancomycin | Biphasic release pattern: initial burst release on day 1, followed by slow and controlled release for up to 28 days | [ | |
| PCL/HA on Ti | Rifampicin | Initial burst release (40% in the first day), followed by sustained release for 32 days | [ |
|
| |||
| CaP on Mg alloy | Zoledronate | Continual gradient increase until 1 week | [ |
| CHI/BG on AISI 316LVM | Gentamicin | Initial burst release in the first week, slow release for up to 56 days | [ |
| halloysite nanotubes/CHI/BG on AISI 315 LVM | Tetracycline hydrochloride | Rapid release within the first 14 days (54% of the drug), followed by slower release for up to 42 days (73% of the drug) | [ |
|
| |||
| CHI/mesoporous silica nanoparticles on Ti | Ibuprofen | Plateau within the first day | [ |
|
| |||
| CHI/amino-functionalized BG on Ti | Vancomycin | Burst release of 42% in the early stages, slow release for up to 14 days | [ |
|
| |||
| HA hydrogel on dental implants (Implantium, Dentum Co. Ltd., Suwon, Korea) | rhBMP2 | Slow and sustained release for up to 35 days | [ |
|
| |||
| HA/BMP2 on Ti | Gentamicin | Release of more than 99% of gentamicin contained in the coating after 2 days | [ |
|
| |||
| HA on Ti6Al4V | Tobramycin | Initial rapid release, followed by a plateau, 90% of the drug released within 180 min | [ |
| Carbonated HA on Ti | Cephalothin, cefamandole, tobramycin and gentamicin | Rapid release: all of the gentamicin within 1 h, 80–90% of the cefamandole and tobramycin within 8 h, 70% of the cephalothin within 16 h | [ |
|
| |||
| CMC on AISI 316LVM | DCF | 1–10 min: burst release following the zero-order release mechanism, 10–30 min: fast release (60% of the drug is released by this point) following the Higuchi release mechanism, 30–360 min: slow release, Higuchi, 360–1440 min: the plateau | [ |
| CHI/gelatin on Ti | Levofloxacine | Gradual release for up to 4 days | [ |
| PAA/PLL/β-CD | Tetracycline | Burst release within the first day, continuous release over the next 15 days, plateau for up to 30 days | [ |
|
| |||
| TNT/polydopamine | Dexamethasone | Slow release over a period of 75 h (maximum drug release is 84%) | [ |
| Periodically tailored TNTs | Indomethacin | A zero-order release mechanism, slow and steady release for up to 17 days (maximum drug release of 50%) | [ |
| (-NH2)- and (-SH)-treated TNTs | Enrofloxacin | Higuchi release mechanism, initial burst release for up to 7 h, followed by slower matrix-controlled release for up to 50 h | [ |
| 1–10 layers of PLGA on TNTs | Ibuprofen | Prolonged and controlled release for up to 40 days with 10 layers of PLGA | [ |
| Silk fibroin on TNTs | Vancomycin | Higuchi release mechanism, initial burst release on the first day (20% of drug released), followed by a slower release, but constant release for up to 40 days | [ |
| Alendronate-grafted HA on TNTs | Raloxifene | Steady and sustained release until 92 h, release rate gradually decreasing from 92 h to 192 h | [ |
|
| |||
| Sr-HA nanocrystals co-immobilized on AZ31 Mg alloy with polydopamine and carboxymethyl CHI | Alendronate | Initial fast release of 25% of the drug within the first day, followed by slower release with 1–4% of the drug released per day for up to 14 days | [ |